Insider Selling: Fulgent Genetics (NASDAQ:FLGT) COO Sells 1,201 Shares of Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie sold 1,201 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $17.60, for a total value of $21,137.60. Following the sale, the chief operating officer owned 369,751 shares of the company’s stock, valued at $6,507,617.60. This represents a 0.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Fulgent Genetics Stock Performance

Shares of NASDAQ:FLGT traded up $0.34 during trading on Thursday, hitting $18.24. The company’s stock had a trading volume of 478,192 shares, compared to its average volume of 502,915. The company has a market capitalization of $518.03 million, a PE ratio of -7.63 and a beta of 0.88. Fulgent Genetics, Inc. has a fifty-two week low of $13.46 and a fifty-two week high of $31.04. The stock’s 50-day moving average price is $16.04 and its two-hundred day moving average price is $21.94.

Fulgent Genetics (NASDAQ:FLGT) last issued its quarterly earnings data on Friday, February 27th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.14. Fulgent Genetics had a negative return on equity of 3.24% and a negative net margin of 23.04%.The firm had revenue of $83.34 million during the quarter, compared to analyst estimates of $85.38 million. Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. On average, equities analysts predict that Fulgent Genetics, Inc. will post -2.81 earnings per share for the current fiscal year.

Institutional Trading of Fulgent Genetics

Several institutional investors have recently added to or reduced their stakes in FLGT. Allianz Asset Management GmbH lifted its position in shares of Fulgent Genetics by 119.6% in the 3rd quarter. Allianz Asset Management GmbH now owns 90,869 shares of the company’s stock worth $2,054,000 after buying an additional 49,485 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Fulgent Genetics by 767.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 299,014 shares of the company’s stock valued at $6,758,000 after buying an additional 264,524 shares during the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in Fulgent Genetics during the fourth quarter worth about $1,739,000. Northwestern Mutual Wealth Management Co. raised its stake in Fulgent Genetics by 2,984,354.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,522,072 shares of the company’s stock worth $39,985,000 after acquiring an additional 1,522,021 shares during the period. Finally, UBS Group AG lifted its holdings in Fulgent Genetics by 288.8% in the fourth quarter. UBS Group AG now owns 83,559 shares of the company’s stock worth $2,195,000 after acquiring an additional 62,070 shares during the last quarter. Institutional investors own 48.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on FLGT shares. Piper Sandler reissued a “neutral” rating and set a $15.00 price objective (down from $30.00) on shares of Fulgent Genetics in a report on Tuesday, May 5th. Wall Street Zen lowered shares of Fulgent Genetics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Zacks Research lowered shares of Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $27.00.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.